Compass Therapeutics (CMPX) Stock Plummets 80% on Trial Data

Key Developments Summary

Compass Therapeutics (NASDAQ:CMPX) shares fell 80% after the company announced mixed results from its Phase 2/3 study of tovecimig in biliary tract cancer. The drug met one key endpoint but failed to show a statistically significant improvement in overall survival.

Trial Data Overview

The combination of tovecimig and paclitaxel demonstrated a median progression-free survival of 4.7 months versus 2.6 months for paclitaxel alone, a positive outcome. However, the study did not meet its overall survival endpoint, with a median of 8.9 months for the combination arm versus 9.4 months for the control arm. Compass noted the result was confounded by 54% of control patients later receiving tovecimig.

Market Impact and Future Outlook

The market's reaction was sharply negative due to the missed survival metric. Compass Therapeutics plans to meet with the FDA to discuss a potential Biologics License Application. Biliary tract cancer affects approximately 26,500 patients annually in the U.S. with limited second-line treatment options.

Summary

Investors reacted to the failure to meet the critical overall survival endpoint. The company's future now hinges on its upcoming dialogue with the FDA regarding the complex trial data.

FAQ

Q: Why did Compass Therapeutics stock fall?
A: The stock dropped 80% after its cancer drug, tovecimig, failed to show a statistically significant improvement in overall survival in a late-stage clinical trial.

Q: What is Compass Therapeutics' next step?
A: The company plans to meet with the U.S. Food and Drug Administration (FDA) to discuss the trial results and a potential path to drug approval.

Source: Investing.com